3rd Party Biotechnology Industry News

Maze Therapeutics has revealed topline phase 2 data for its [...]

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion [...]

Sarepta Therapeutics has shared initial clinical data on two siRNA [...]

Full 12-month data from Ocugen’s phase 2 eye disease gene [...]

Shionogi has struck a deal to take full control of [...]

Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s [...]

Apogee Therapeutics has published phase 2 eczema data that suggest [...]

Sanofi has returned to T-cell engager territory via an agreement [...]

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease [...]

Genentech is halting development of an antibody for two rare [...]